Shengfang is a co-founder, President and CEO, and Board of Director of Ensem Therapeutics. Prior to her role as CEO, she served as the President and Chief Scientific Officer, driving ENSEM’s strategic initiatives, technology platforms, and R&D. Previously, she was Vice President of Discovery Biology at Editas Medicine (EDIT), a clinical-stage gene editing company. Her teams pioneered the discovery of advanced CRISPR gene and cell therapies focusing on ophthalmology, neural diseases, and oncology. Earlier in her career, Dr. Jin was Senior Director of Biology at Agios Pharmaceuticals, leading the Small Molecule Cancer Metabolism and Rare Genetic Disease Portfolios that culminated in the approved & first-in-class products (IDHIFA^®, TIBSOVO^®, PYRUKYND^®) and other clinical stage programs. She has also held roles of increasing responsibilities in other Cambridge drug discovery companies. Shengfang is a passionate & enthusiastic motivator, empowering team members to lead and shine.

Shengfang is co-author/co-inventor of over 80 peer-reviewed publications and issued patents. She holds a Ph.D. in Molecular Biology and Microbiology from Tufts Medical School (Boston) and obtained postdoctoral training in Oncology and Tumor Immunology at Harvard Medical School (Boston) as an NIH Fellow.